Covid-19 Impact on Immuno-oncology Therapy Market, Global Research Reports 2020-2021

2 Global Immuno-oncology Therapy Quarterly Market Size Analysis

• 2.1 Immuno-oncology Therapy Business Impact Assessment - COVID-19
  • 2.1.1 Global Immuno-oncology Therapy Market Size, Pre-COVID-19 and Post- COVID-19 Comparison, 2015-2026
• 2.2 Global Immuno-oncology Therapy Quarterly Market Size 2020-2021
• 2.3 COVID-19-Driven Market Dynamics and Factor Analysis
  • 2.3.1 Drivers
  • 2.3.2 Restraints
  • 2.3.3 Opportunities
  • 2.3.4 Challenges

3 Quarterly Competitive Assessment, 2020

• 3.1 By Players, Global Immuno-oncology Therapy Quarterly Market Size, 2019 VS 2020
• 3.2 By Players, Immuno-oncology Therapy Headquarters and Area Served
• 3.3 Date of Key Players Enter into Immuno-oncology Therapy Market
• 3.4 Key Players Immuno-oncology Therapy Product Offered
• 3.5 Mergers & Acquisitions, Expansion Plans

4 Impact of Covid-19 on Immuno-oncology Therapy Segments, By Type

• 4.1 Introduction
  • 1.4.1 Monoclonal Antibodies
  • 1.4.2 Immune Checkpoint Inhibitors
  • 1.4.3 Immune System Modulators
  • 1.4.4 Cancer Vaccines
  • 1.4.5 Others
• 4.2 By Type, Global Immuno-oncology Therapy Market Size, 2019-2021

5 Impact of Covid-19 on Immuno-oncology Therapy Segments, By Application

• 5.1 Overview
  • 5.5.1 Hospitals
  • 5.5.2 Ambulatory Surgical Center
  • 5.5.3 Others
• 5.2 By Application, Global Immuno-oncology Therapy Market Size, 2019-2021
  • 5.2.1 By Application, Global Immuno-oncology Therapy Market Size by Application, 2019-2021

6 Geographic Analysis

• 6.1 Introduction
• 6.2 North America
  • 6.2.1 Macroeconomic Indicators of US
  • 6.2.2 US
  • 6.2.3 Canada
• 6.3 Europe
  • 6.3.1 Macroeconomic Indicators of Europe
  • 6.3.2 Germany
  • 6.3.3 France
  • 6.3.4 UK
  • 6.3.5 Italy
• 6.4 Asia-Pacific
  • 6.4.1 Macroeconomic Indicators of Asia-Pacific
  • 6.4.2 China
  • 6.4.3 Japan
  • 6.4.4 South Korea
  • 6.4.5 India
  • 6.4.6 ASEAN
• 6.5 Rest of World
  • 6.5.1 Latin America
  • 6.5.2 Middle East and Africa

7 Company Profiles

• 7.1 Amgen
  • 7.1.1 Amgen Business Overview
  • 7.1.2 Amgen Immuno-oncology Therapy Quarterly Revenue, 2020
  • 7.1.3 Amgen Immuno-oncology Therapy Product Introduction
  • 7.1.4 Amgen Response to COVID-19 and Related Developments
• 7.2 AstraZeneca
  • 7.2.1 AstraZeneca Business Overview
  • 7.2.2 AstraZeneca Immuno-oncology Therapy Quarterly Revenue, 2020
  • 7.2.3 AstraZeneca Immuno-oncology Therapy Product Introduction
  • 7.2.4 AstraZeneca Response to COVID-19 and Related Developments
• 7.3 Bristol-Myers Squibb
  • 7.3.1 Bristol-Myers Squibb Business Overview
  • 7.3.2 Bristol-Myers Squibb Immuno-oncology Therapy Quarterly Revenue, 2020
  • 7.3.3 Bristol-Myers Squibb Immuno-oncology Therapy Product Introduction
  • 7.3.4 Bristol-Myers Squibb Response to COVID-19 and Related Developments
• 7.4 Eli-Lilly
  • 7.4.1 Eli-Lilly Business Overview
  • 7.4.2 Eli-Lilly Immuno-oncology Therapy Quarterly Revenue, 2020
  • 7.4.3 Eli-Lilly Immuno-oncology Therapy Product Introduction
  • 7.4.4 Eli-Lilly Response to COVID-19 and Related Developments
• 7.5 Roche
  • 7.5.1 Roche Business Overview
  • 7.5.2 Roche Immuno-oncology Therapy Quarterly Revenue, 2020
  • 7.5.3 Roche Immuno-oncology Therapy Product Introduction
  • 7.5.4 Roche Response to COVID-19 and Related Developments
• 7.6 GlaxoSmithKline
  • 7.6.1 GlaxoSmithKline Business Overview
  • 7.6.2 GlaxoSmithKline Immuno-oncology Therapy Quarterly Revenue, 2020
  • 7.6.3 GlaxoSmithKline Immuno-oncology Therapy Product Introduction
  • 7.6.4 GlaxoSmithKline Response to COVID-19 and Related Developments
• 7.7 Janssen Biotech
  • 7.7.1 Janssen Biotech Business Overview
  • 7.7.2 Janssen Biotech Immuno-oncology Therapy Quarterly Revenue, 2020
  • 7.7.3 Janssen Biotech Immuno-oncology Therapy Product Introduction
  • 7.7.4 Janssen Biotech Response to COVID-19 and Related Developments
• 7.8 Merck
  • 7.8.1 Merck Business Overview
  • 7.8.2 Merck Immuno-oncology Therapy Quarterly Revenue, 2020
  • 7.8.3 Merck Immuno-oncology Therapy Product Introduction
  • 7.8.4 Merck Response to COVID-19 and Related Developments
• 7.9 Novartis
  • 7.9.1 Novartis Business Overview
  • 7.9.2 Novartis Immuno-oncology Therapy Quarterly Revenue, 2020
  • 7.9.3 Novartis Immuno-oncology Therapy Product Introduction
  • 7.9.4 Novartis Response to COVID-19 and Related Developments
• 7.10 Pfizer
  • 7.10.1 Pfizer Business Overview
  • 7.10.2 Pfizer Immuno-oncology Therapy Quarterly Revenue, 2020
  • 7.10.3 Pfizer Immuno-oncology Therapy Product Introduction
  • 7.10.4 Pfizer Response to COVID-19 and Related Developments
• 7.11 Sanofi
  • 7.11.1 Sanofi Business Overview
  • 7.11.2 Sanofi Immuno-oncology Therapy Quarterly Revenue, 2020
  • 7.11.3 Sanofi Immuno-oncology Therapy Product Introduction
  • 7.11.4 Sanofi Response to COVID-19 and Related Developments
• 7.12 Spectrum Pharmaceuticals
  • 7.12.1 Spectrum Pharmaceuticals Business Overview
  • 7.12.2 Spectrum Pharmaceuticals Immuno-oncology Therapy Quarterly Revenue, 2020
  • 7.12.3 Spectrum Pharmaceuticals Immuno-oncology Therapy Product Introduction
  • 7.12.4 Spectrum Pharmaceuticals Response to COVID-19 and Related Developments
• 7.13 Takeda
  • 7.13.1 Takeda Business Overview
  • 7.13.2 Takeda Immuno-oncology Therapy Quarterly Revenue, 2020
  • 7.13.3 Takeda Immuno-oncology Therapy Product Introduction
  • 7.13.4 Takeda Response to COVID-19 and Related Developments

8 Key Findings

9 Appendix

• 9.1 About US